These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 22277093)

  • 21. Tumor-specific anti-epidermal growth factor receptor variant III monoclonal antibodies: use of the tyramine-cellobiose radioiodination method enhances cellular retention and uptake in tumor xenografts.
    Reist CJ; Archer GE; Kurpad SN; Wikstrand CJ; Vaidyanathan G; Willingham MC; Moscatello DK; Wong AJ; Bigner DD; Zalutsky MR
    Cancer Res; 1995 Oct; 55(19):4375-82. PubMed ID: 7671250
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Camelid single-domain antibody-fragment engineering for (pre)clinical in vivo molecular imaging applications: adjusting the bullet to its target.
    De Vos J; Devoogdt N; Lahoutte T; Muyldermans S
    Expert Opin Biol Ther; 2013 Aug; 13(8):1149-60. PubMed ID: 23675652
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effective therapeutic approach for head and neck cancer by an engineered minibody targeting the EGFR receptor.
    Kim YP; Park D; Kim JJ; Chi WJ; Lee SH; Lee SY; Kim S; Chung JM; Jeon J; Lee BD; Shin JH; Lee YI; Cho H; Lee JM; Kang HC
    PLoS One; 2014; 9(12):e113442. PubMed ID: 25438047
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Extracellular region of epidermal growth factor receptor: a potential target for anti-EGFR drug discovery.
    Dokala A; Thakur SS
    Oncogene; 2017 Apr; 36(17):2337-2344. PubMed ID: 27775071
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Eradication of established tumors by a fully human monoclonal antibody to the epidermal growth factor receptor without concomitant chemotherapy.
    Yang XD; Jia XC; Corvalan JR; Wang P; Davis CG; Jakobovits A
    Cancer Res; 1999 Mar; 59(6):1236-43. PubMed ID: 10096554
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A novel approach in the treatment of cancer: targeting the epidermal growth factor receptor.
    Ciardiello F; Tortora G
    Clin Cancer Res; 2001 Oct; 7(10):2958-70. PubMed ID: 11595683
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Combined epidermal growth factor receptor targeting with the tyrosine kinase inhibitor gefitinib (ZD1839) and the monoclonal antibody cetuximab (IMC-C225): superiority over single-agent receptor targeting.
    Matar P; Rojo F; Cassia R; Moreno-Bueno G; Di Cosimo S; Tabernero J; Guzmán M; Rodriguez S; Arribas J; Palacios J; Baselga J
    Clin Cancer Res; 2004 Oct; 10(19):6487-501. PubMed ID: 15475436
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Novel single-domain antibodies against the EGFR domain III epitope exhibit the anti-tumor effect.
    Chen T; Liu X; Hong H; Wei H
    J Transl Med; 2020 Oct; 18(1):376. PubMed ID: 33023595
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Expression of EGFRvIII in thyroid carcinoma: immunohistochemical study by camel antibodies.
    Omidfar K; Moinfar Z; Sohi AN; Tavangar SM; Haghpanah V; Heshmat R; Kashanian S; Larijani B
    Immunol Invest; 2009; 38(2):165-80. PubMed ID: 19330625
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Epidermal growth factor receptor: pathway, therapies, and pipeline.
    Goffin JR; Zbuk K
    Clin Ther; 2013 Sep; 35(9):1282-303. PubMed ID: 24054705
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Development of tetravalent IgG1 dual targeting IGF-1R-EGFR antibodies with potent tumor inhibition.
    Croasdale R; Wartha K; Schanzer JM; Kuenkele KP; Ries C; Mayer K; Gassner C; Wagner M; Dimoudis N; Herter S; Jaeger C; Ferrara C; Hoffmann E; Kling L; Lau W; Staack RF; Heinrich J; Scheuer W; Stracke J; Gerdes C; Brinkmann U; Umana P; Klein C
    Arch Biochem Biophys; 2012 Oct; 526(2):206-18. PubMed ID: 22464987
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Rational bases for the development of EGFR inhibitors for cancer treatment.
    Bianco R; Gelardi T; Damiano V; Ciardiello F; Tortora G
    Int J Biochem Cell Biol; 2007; 39(7-8):1416-31. PubMed ID: 17596994
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The monoclonal antibody CH12 augments 5-fluorouracil-induced growth suppression of hepatocellular carcinoma xenografts expressing epidermal growth factor receptor variant III.
    Jiang H; Dong Q; Luo X; Shi B; Wang H; Gao H; Kong J; Zhang J; Li Z
    Cancer Lett; 2014 Jan; 342(1):113-20. PubMed ID: 24007863
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Potential for molecularly targeted therapy against epidermal growth factor receptor ligands.
    Miyamoto S; Fukami T; Yagi H; Kuroki M; Yotsumoto F
    Anticancer Res; 2009 Mar; 29(3):823-30. PubMed ID: 19414315
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparison of the biodistribution and tumor targeting of two 99mTc-labeled anti-EGFR nanobodies in mice, using pinhole SPECT/micro-CT.
    Gainkam LO; Huang L; Caveliers V; Keyaerts M; Hernot S; Vaneycken I; Vanhove C; Revets H; De Baetselier P; Lahoutte T
    J Nucl Med; 2008 May; 49(5):788-95. PubMed ID: 18413403
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Development and evaluation of a cetuximab-based imaging probe to target EGFR and EGFRvIII.
    Aerts HJ; Dubois L; Hackeng TM; Straathof R; Chiu RK; Lieuwes NG; Jutten B; Weppler SA; Lammering G; Wouters BG; Lambin P
    Radiother Oncol; 2007 Jun; 83(3):326-32. PubMed ID: 17531336
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Critical update and emerging trends in epidermal growth factor receptor targeting in cancer.
    Baselga J; Arteaga CL
    J Clin Oncol; 2005 Apr; 23(11):2445-59. PubMed ID: 15753456
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Properties, production, and applications of camelid single-domain antibody fragments.
    Harmsen MM; De Haard HJ
    Appl Microbiol Biotechnol; 2007 Nov; 77(1):13-22. PubMed ID: 17704915
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A new antibody recognizing the vIII mutation of human epidermal growth factor receptor.
    Ohman L; Gedda L; Hesselager G; Larsson R; Nister M; Stigbrand T; Wester K; Carlsson J
    Tumour Biol; 2002; 23(2):61-9. PubMed ID: 12065843
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Monoclonal antibody-based therapeutics, targeting the epidermal growth factor receptor family: from herceptin to Pan HER.
    Moradi-Kalbolandi S; Hosseinzade A; Salehi M; Merikhian P; Farahmand L
    J Pharm Pharmacol; 2018 Jul; 70(7):841-854. PubMed ID: 29574771
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.